Clinical Trials Logo

Filter by:
NCT ID: NCT04341155 Recruiting - Clinical trials for Toxoplasmosis, Cerebral

Dexamethasone for Cerebral Toxoplasmosis

De-Tox
Start date: April 16, 2021
Phase: Phase 2
Study type: Interventional

Toxoplasma gondii infects over one third of the global human population. Cerebral toxoplasmosis is the most common opportunistic infection in HIV patients resulting in up to 50% of mortality with proper treatment and 80% without it. The fatality mainly due to the brain edema resulted from the mass effect lesion. In addition of anti toxoplasmosis given, adjunctive therapy such as steroid is recommended in order to reduce brain edema, but the dose and duration of administration in cerebral toxoplasmosis has not been evaluated in a clinical trial. Adjunctive therapy given in cerebral toxoplasmosis patients still remains unclear. Moreover, its safety in immunodeficiency cases is still debatable.

NCT ID: NCT04489719 Recruiting - Clinical trials for Metastatic Prostate Carcinoma

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Start date: April 16, 2021
Phase:
Study type: Observational

This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Furthermore, many men with notably advanced disease have been found to have abnormalities in DNA repair. The purpose of this research is to study the role of a DNA repair pathway in prostate cancer, specifically in response to administration of radium-223, an FDA-approved drug known to cause DNA damage to cancerous cells. Understanding how defects in the DNA repair pathway affects radium-223 treatment of prostate, may help doctors help plan effective treatment in future patients.

NCT ID: NCT04604197 Recruiting - Clinical trials for Coronary Artery Disease

ANGiographic Evaluation of Left Main Coronary Artery INtErvention

ANGELINE
Start date: April 16, 2021
Phase: N/A
Study type: Interventional

To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.

NCT ID: NCT04625647 Recruiting - Clinical trials for Stage IV Lung Cancer AJCC v8

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Start date: April 16, 2021
Phase: Phase 2
Study type: Interventional

This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.

NCT ID: NCT04658342 Recruiting - Clinical trials for Cancer of Head and Neck

Effects of Oral Cancer Treatments on Upper Esophageal Opening During Swallowing

Start date: April 16, 2021
Phase:
Study type: Observational

The purpose of this study is to investigate post-operative and post-radiation upper esophageal sphincter opening measures in oral cancer patients, compare measures to age- and gender-matched healthy adults, and determine relationships with patient swallowing outcomes and quality of life.

NCT ID: NCT04663750 Recruiting - Eye Diseases Clinical Trials

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

TIGER
Start date: April 16, 2021
Phase: Phase 3
Study type: Interventional

The centre of the retina (macula) at the back of the eye contains cells that give us our central vision that we use for reading and recognising faces. These cells can be damaged by a disease called wet age-related macular degeneration (AMD), where new abnormal blood vessels grow through the macula and leak fluid. This can affect vision. In some cases, wet AMD can also cause a bleed under the macula, known as a submacular haemorrhage (SMH), which can lead to marked and persistent loss of vision in the eye. The current standard treatment for wet AMD is to give injections containing 'anti-VEGF' drugs into the eye. Anti-VEGF drugs reduce the leakage of fluid so that the macula can become dry again and sight can improve. Anti-VEGFs are also the current standard of care for SMH, mainly because there is no licensed treatment for the SMH itself (patients with SMH were excluded from most wet AMD studies). The purpose of this study therefore is to compare two treatments: 1. Standard treatment for wet AMD (anti-VEGF injections). 2. Standard treatment above plus surgery. This study will find out if having surgery alongside anti-VEGF injections can improve vision further over the current standard treatment of anti-VEGF injections alone.

NCT ID: NCT04693221 Recruiting - Epilepsy Clinical Trials

Optimization of the Parameters of Vagal Nerve Stimulation

OPSTIMVAG
Start date: April 16, 2021
Phase: N/A
Study type: Interventional

Vagal nerve stimulation (VNS) is one of the neuromodulation techniques that can be indicated in patients suffering from refractory epilepsies, especially when an open resection has failed or is not indicated. However to date it is not possible to predict which patients will respond and what are the best parameters of stimulation to be set (pulse width, frequency and intensity). It has been shown that responders to VNS have reduced interictal cortical synchronicity on scalp EEG based on phase lag index (PLI), a marker of functional connectivity (Fc) The aim of this study is to test the following hypothesis: setting the parameters of stimulation on the basis of the lowest values of Phase Lag Index (PLI) obtained on scalp EEG with different settings of parameters (as compared with a randomly chosen set of commonly used parameters) will increase the rate of responders to VNS.

NCT ID: NCT04730258 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

TWT-202
Start date: April 16, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

NCT ID: NCT04737707 Recruiting - Clinical trials for Autism Spectrum Disorders

Dialectical Behavior Therapy for Adults With Autism Spectrum Disorders

Autisemo
Start date: April 16, 2021
Phase: N/A
Study type: Interventional

Dialectical Behavior Therapy (DBT; Linehan, 1993) effectively diminishes emotion dysregulation and self-harm behaviors in a number of disorders. However, to our knowledge, no studies have investigated the efficacy of DBT to treat emotional dysregulation associated with self-harm and suicidal behaviors in adults with ASD without intellectual disability. This randomized controlled study trial aims to assess the efficacy of a 5-month DBT intervention in adults with ASD without intellectual disability who present with self-harm and/or suicidal behaviors.

NCT ID: NCT04753567 Recruiting - Clinical trials for Osteoarthritis, Knee

nCap Pain Relief Patch vs. Placebo

Start date: April 16, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether use of the nCap Medical Nano-Capacitive pain relief patch reduces subject pain as measured by subject pain scores, WOMAC scores (pain, stiffness and physical function), global assessment scores, and pain medication change as compared to participants randomly assigned to the sham patch group.